1217174-18-9
Chemical Structure
Zafirlukast-d7
- CAS No.: 1217174-18-9
- Formula:C31H26D7N3O6S
- Molecular Weight:582.72
IUPAC Name: cyclopentyl (3-(2-methoxy-4-(((2-(methyl-d3)phenyl-3,4,5,6-d4)sulfonyl)carbamoyl)benzyl)-1-methyl-1H-indol-5-yl)carbamate
InChIKey: YEEZWCHGZNKEEK-WRQTXKASSA-N
SMILES: C(C=1C=2C(N(C)C1)=CC=C(NC(OC3CCCC3)=O)C2)C4=C(OC)C=C(C(NS(=O)(=O)C5=C(C([2H])([2H])[2H])C(=C(C(=C5[2H])[2H])[2H])[2H])=O)C=C4
Biological Activity: Zafirlukast-d7 is the deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Zafirlukast-d7 | Zafirlukast-d7 is the deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Zafirlukast (Standard) | 99.15% | Zafirlukast (Standard) is the analytical standard of Zafirlukast. This product is intended for research and analytical applications. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Zafirlukast-13C,d6 | Zafirlukast-13C,d6 is the 13C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Zafirlukast-d6 | Zafirlukast-d6 is deuterated labeled Zafirlukast (HY-17492). Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Zafirlukast-13C,d3 | Zafirlukast-13C,d3 is the 13C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Zafirlukast | 99.87% | Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Finnerty JP, et al. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):746-9. [Content Brief]
